ClinicalTrials.gg
Active, not recruitingNCT04776434SUCCESS PTAUpdated Nov 6, 2026

SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study

An interventional study of SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB) in Peripheral Artery Disease, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 27 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
723
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.

Enrollment
13th of 126
723 · median 107
Started
2021
with 12 others
No phase
85 of 173
8 open now
Primary completion
2024-11
later than 7 of 28 live
Registered
131st of 173
by date

Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 13th largest by enrollment of the 126 interventional ones that give a count, is one of 13 that started in 2021, is one of 85 with no phase, reaches primary completion later than 7 of the 28 other live ones, and was the 131st registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Peripheral Arterial Disease with a site in Germany, or all of them as a file.
02

Study summary

Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).

Read the detailed description

Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).

This study will capture data from the use of the SELUTION SLR according to its approved labelling. Each indication for use will have a specific data sets in addition to generic data sets that are common across all indications.

Patients will be followed for 5 years post-procedure to obtain safety and efficacy data. A health economic analysis will be made comparing data between countries within the study and to published data for existing treatment options. Generic and disease specific Patient Reported Outcome Measures (PROMs) will be used to measure the impact of the intervention on the overall health status of patients.

Imaging data collection for patients whose standard of care includes imaging follow-up will be captured and analysed.

Data will be collected from any subject who receives a CE marked device for treatment of a peripheral (i.e. non-cardiovascular) vascular lesion.

Data analysis will be stratified by lesion location.

03

Conditions studied

  • Peripheral Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject age is ≥ 18 years
  • Subject is able and willing to provide
  • Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the current Instruction for use.

Exclusion criteria

Exclusion Criteria:

  • In the opinion of the treating investigator the subject has a of less than 12 months
  • In the opinion of the treating investigator the subject is unlikely to comply with the study follow-up regime
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
723 participants (actual)

Study arms

  • Experimental
    SELUTION SLR™ DEB

    Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.

    Device: SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)

Interventions

  • DeviceSELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)

    This study will capture data from the use of the SELUTION SLR according to its approved labelling.

06

What researchers measure

Primary outcomes

  1. Clinically Driven Target Lesion Revascularization

    The primary endpoint will be freedom from Clinically Driven Target Lesion Revascularisation (CD-TLR) at 1-year post-intervention.

    Time frame: 1 year after treatment

Secondary outcomes

  1. Device Success

    Successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure.

    Time frame: At end of procedure

  2. Procedure success

    Device success and residual stenosis ≤50% at the end of the procedure.

    Time frame: At end of procedure

  3. Clinical success

    Procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion or TLR) prior to discharge.

    Time frame: At discharge after procedure

  4. Major Adverse Limb Events (MALE) composite endpoint

    Severe limb ischemia leading to an intervention or major vascular amputation (above the ankle).

    Time frame: At discharge after procedure and 1, 6, 12, 24, 36, 48 and 60 months

  5. Major Cardiac Events Major Cardiac Events

    MI, Stroke, Cardiovascular death

    Time frame: At 1, 6, 12, 24, 36,48, 60 months

  6. Death

    All-cause, cardiac, device related, procedure related

    Time frame: At 1, 6, 12, 24, 36, 48, 60 months

  7. TLR

    Number of Target Lesion Revascularizations

    Time frame: At 1, 6, 12, 24, 36, 48, 60 months

  8. TVR

    Number of Target Vessel Revascularizations

    Time frame: At 1, 6, 12, 24, 36, 48, 60 months

  9. Time to first CD-TLR

    Time to first Clinically Driven Target Lesion Revascularization

    Time frame: up to 60 months

  10. Target limb revascularization

    Number of Target limb revascularizations

    Time frame: At 1, 6, 12, 24, 36, 48, 60 months

  11. Thrombosis at the target site

    Number of Thrombosis at the target site

    Time frame: At 1 month

  12. Amputation

    Number of Amputations

    Time frame: up to 60 months

  13. Rutherford Classification score

    Change in Rutherford Classification score from baseline (Scale from 0 to 6, higher score means worse outcome.

    Time frame: At 6, 12, 24, 36, 48, 60 months

  14. Ankle Brachial Index (ABI)

    Change in ankle brachial index (ABI) from baseline

    Time frame: At 6, 12 months only

  15. Pedal pulse

    Presence of Pedal pulse

    Time frame: 6, 12 months only

  16. Wound status if applicable

    location, size, infection, status, Wound, Ischemia and Foot Infection (WIfI) classification system score

    Time frame: 6, 12 months only

  17. Kawarada Classification score

    Change from baseline to end of procedure to assess change in severity of Pedal Artery Disease

    Time frame: At end of procedure

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2024, 45 months.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 45 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2021
First posted
Mar 1, 2021
StartActual
Feb 8, 2021
Primary completionActual
Nov 10, 2024
CompletionEst.
Dec 31, 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04776434
Lead sponsor
M.A. Med Alliance S.A.
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Feb 8, 2021
Primary completion
Nov 10, 2024
Completion
Dec 31, 2028 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion